Literature DB >> 16291715

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.

B Søgaard1, H Mengel, N Rao, F Larsen.   

Abstract

The pharmacokinetics of escitalopram (S-citalopram) and its principal metabolite, S-demethylcitalopram (S-DCT), were investigated after intravenous and oral administration to healthy subjects. After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1,100 L, respectively. After oral administration of single or multiple doses, the absorption was relatively fast, with the maximum observed plasma or serum concentration (C(max)) attained after 3 to 4 hours. The mean half-lives were 27 and 33 hours, respectively; steady state was attained within 10 days. The area under the plasma or serum concentration time curve from time zero to 24 hours and C(max) was both linear and proportional to the dose. The apparent volume of distribution was around 20 L/kg. Comparison of the systemic and oral clearance implied a high absolute bioavailability. There was no evidence of interconversion from S-citalopram to R-citalopram either in plasma or in urine. Concurrent intake of food had no effect on the pharmacokinetics of escitalopram or its metabolite. All treatments were well tolerated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291715     DOI: 10.1177/0091270005280860

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  46 in total

1.  Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects.

Authors:  Andrew H Kemp; Tim Outhred; Sasha Saunders; Andre R Brunoni; Pradeep J Nathan; Gin S Malhi
Journal:  Psychopharmacology (Berl)       Date:  2013-12-15       Impact factor: 4.530

2.  Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques.

Authors:  Sarah R Delaney; Paul R V Malik; Cristiana Stefan; Andrea N Edginton; David A Colantonio; Shinya Ito
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

3.  [Expanding therapeutic reference ranges using dose-related reference ranges].

Authors:  E Haen; C Greiner; W Bader; M Wittmann
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

4.  Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study.

Authors:  Barbara Drueke; Julia Baetz; Maren Boecker; Olaf Moeller; Christoph Hiemke; Gerd Gründer; Siegfried Gauggel
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

5.  A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk.

Authors:  Etienne Weisskopf; Monia Guidi; Céline J Fischer; Myriam Bickle Graz; Etienne Beaufils; Kim An Nguyen; Mathilde Morisod Harari; Sylvie Rouiller; Sophie Rothenburger; Pascal Gaucherand; Behrouz Kassai-Koupai; Cristina Borradori Tolsa; Manuella Epiney; Jean-François Tolsa; Yvan Vial; Jean-Michel Hascoët; Olivier Claris; Chin B Eap; Alice Panchaud; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2020-04-14       Impact factor: 4.335

6.  Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal.

Authors:  Freek van Gorp; Stephen Duffull; L Peter Hackett; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

7.  Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment.

Authors:  Chase H Bourke; Catherine F Capello; Swati M Rogers; Megan L Yu; Katherine A Boss-Williams; Jay M Weiss; Zachary N Stowe; Michael J Owens
Journal:  Psychopharmacology (Berl)       Date:  2013-02-24       Impact factor: 4.530

Review 8.  Escitalopram: in the treatment of major depressive disorder in adolescent patients.

Authors:  Lily P H Yang; Lesley J Scott
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

9.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

10.  The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Jeff Florian; Margaret Kirshner; Andrea Fagiolini; David J Kupfer; Marc R Gastonguay; Gail Kepple; Yan Feng; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-02       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.